Dr Lalchandani Labs Ltd Financials
Company Logo

Dr Lalchandani Labs Ltd Financial Statement

Dr Lalchandani Labs Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

No Data Available

Dr Lalchandani Labs Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Total Revenue Annual5.04
Operating Expenses Annual4.96
Operating Profit Annual0.09
Interest Annual0.99
Depreciation0.59
Net Profit Annual-1.56
Tax AnnualTBA

Dr Lalchandani Labs Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Cash Flow at the Beginning3.53
Cash Flow from OperationsTBA
Cash Flow from Investing-0.20
Cash Flow from Financing-0.23
Cash Flow at the End3.10

Dr Lalchandani Labs Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
PBDIT Margin (%)1.79
PBIT Margin (%)-11.31
PBT Margin (%)0.20
Net PROFIT Margin (%)-30.95
Return On Networth / Equity (%)-16.11
Return On Networth /Employed (%)-3.69
Return On Assets (%)-10.21
Total Debt / Equity (X)0.60
Asset Turnover Ratio (%)0.33

Dr Lalchandani Labs Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Fixed Assets Annual5.39
Total Current Assets Annual11.02
Non Current Assets Annual6.70
Total Shareholders Funds Annual8.92
Total Assets Annual17.72

Dr Lalchandani Labs Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Sep 20, 2024, Dr Lalchandani Labs Ltd has a market capitalization of 6.81 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Dr Lalchandani Labs Ltd is debt-free with a debt-to-equity ratio of 0.36.
In FY 2023 , Dr Lalchandani Labs Ltd recorded a total revenue of approximately 4.81 Cr marking a significant milestone in the company's financial performance.
Dr Lalchandani Labs Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.4% and -0.4% annually, respectively..
Dr Lalchandani Labs Ltd's current PE ratio is 10.98.
Dr Lalchandani Labs Ltd's ROCE averaged 5.0% from the FY ending March 2022 to 2024, with a median of 7.7%. It peaked at 11.6% in March 2022, reflecting strong capital efficiency over the period..
Dr Lalchandani Labs Ltd's latest EBIT is Rs. 1 Cr, surpassing the average EBIT of Rs. 0.75 Cr over the 5 years..